Atara Biotherapeutics (ATRA) Stock Forecast for 2024, 2025, 2026. Sell or Buy Prediction







A Comprehensive Guide to RoadRunner Auto Transport Services

October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services

If you want to ship your car from one city to another, why not hire the experts to do everything for you? They…
Mastering Trading Indicators: Your Essential Toolkit For Success

October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success

Often investors struggle to identify profitable trades consistently. Trading indicators provide essential data to guide trading decisions. This article explains key indicators and…
Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…

Atara Biotherapeutics (ATRA) Stock Forecast for 2024, 2025, 2026. Sell or Buy?

Updated: December 5, 2024 (09:40)

Sector: Healthcare

The share price of Atara Biotherapeutics, Inc. (ATRA) now

Latest session on the 4th of December for
Atara Biotherapeutics, Inc. is negative
Trading Volume: 91511
Open: 12.8 /  High: 13.34 /  Low: 12.32
What analysts predict: $14.75
52-week High/Low: $39.5 / $6.5
50-Day Moving Average: $9.54 — support level today
200-Day Moving Average: $12.29 — support level today

Are you interested in Atara Biotherapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Atara Biotherapeutics stock price in 2025, 2026, 2027. How much will one Atara Biotherapeutics share be worth in 2025 - 2027?

When should I take profit in Atara Biotherapeutics stock? When should I record a loss on Atara Biotherapeutics stock? What are analysts' forecasts for Atara Biotherapeutics stock? What is the future of Atara Biotherapeutics stock? We forecast Atara Biotherapeutics stock performance using neural networks based on historical data on Atara Biotherapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Atara Biotherapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Atara Biotherapeutics shares. This happens once a day.


Historical and forecast chart of Atara Biotherapeutics stock

The chart below shows the historical price of Atara Biotherapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Atara Biotherapeutics stock price can be found in the table below.

Long-term forecasts by years.

Atara Biotherapeutic, Inc., a turnkey T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. He is developing tabelecleucel, a T-cell immunotherapy phase III clinical trial for the treatment of rituximab-refractory Epstein-Barr virus (EBV) associated with post-transplant lymphoproliferative disorder, as well as other EBV-related hematological and solid tumors, including carcinoma of the nasopharynx. The company is also developing next-generation CAR T immunotherapy for patients with hematologic malignancies and solid tumors, as well as viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 For B-cell lymphomas, and ATA188, which are in phase I clinical trials for the treatment of multiple sclerosis. He also develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms tumor 1; and ATA621 for BK and JCV. The company has a licensing agreement with the Sloan Kettering Memorial Cancer Center; a license agreement for cooperation in research and development with the Kimr Berghofer Medical Research Institute; and strategic cooperation with the H. Lee Moffitt Cancer Center. Atara Biotherapeutic, Inc. The company was founded in 2012 and is headquartered in South San Francisco, California.

Trending Themes in the Healthcare Sector

Atara Biotherapeutics daily forecast for a month

Date Target Pes. Opt. Vol., %
Dec 07 12.34 12.13 12.51 3.14
Dec 08 12.33 12.24 12.53 2.42
Dec 09 12.01 11.89 12.17 2.37
Dec 10 12.19 11.95 12.28 2.72
Dec 11 12.05 11.92 12.33 3.43
Dec 12 12.18 11.90 12.45 4.61
Dec 13 12.07 11.92 12.34 3.52
Dec 14 11.96 11.87 12.24 3.11
Dec 15 11.88 11.65 12.14 4.19
Dec 16 11.59 11.41 11.70 2.53
Dec 17 11.68 11.41 11.88 4.18
Dec 18 11.99 11.73 12.13 3.47
Dec 19 11.87 11.71 12.06 2.98
Dec 20 11.78 11.66 11.88 1.85
Dec 21 11.73 11.48 11.83 3.00
Dec 22 11.60 11.45 11.86 3.59
Dec 23 11.63 11.45 11.74 2.56
Dec 24 11.60 11.36 11.71 3.10
Dec 25 11.45 11.23 11.54 2.75
Dec 26 11.52 11.39 11.78 3.40
Dec 27 11.62 11.51 11.72 1.85
Dec 28 11.35 11.27 11.44 1.57
Dec 29 11.38 11.14 11.46 2.88
Dec 30 11.57 11.48 11.75 2.42
Dec 31 11.84 11.70 12.06 3.07
Jan 01 12.05 11.80 12.34 4.63
Jan 02 12.12 12.01 12.40 3.27
Jan 03 12.09 11.81 12.35 4.51
Jan 04 11.76 11.52 11.84 2.76
Jan 05 11.78 11.51 12.03 4.54

Atara Biotherapeutics Daily Price Targets


Atara Biotherapeutics Stock Forecast 12-07-2024.

Forecast target price for 12-07-2024: $12.34.
Negative dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 3.049%.
Pessimistic target level: 12.13
Optimistic target level: 12.51

Atara Biotherapeutics Stock Forecast 12-08-2024.

Forecast target price for 12-08-2024: $12.33.
Negative dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 2.361%.
Pessimistic target level: 12.24
Optimistic target level: 12.53

Atara Biotherapeutics Stock Forecast 12-09-2024.

Forecast target price for 12-09-2024: $12.01.
Negative dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 2.311%.
Pessimistic target level: 11.89
Optimistic target level: 12.17

Atara Biotherapeutics Stock Forecast 12-10-2024.

Forecast target price for 12-10-2024: $12.19.
Positive dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 2.652%.
Pessimistic target level: 11.95
Optimistic target level: 12.28

Atara Biotherapeutics Stock Forecast 12-11-2024.

Forecast target price for 12-11-2024: $12.05.
Negative dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 3.312%.
Pessimistic target level: 11.92
Optimistic target level: 12.33

Atara Biotherapeutics Stock Forecast 12-12-2024.

Forecast target price for 12-12-2024: $12.18.
Positive dynamics for Atara Biotherapeutics shares will prevail with possible volatility of 4.404%.
Pessimistic target level: 11.90
Optimistic target level: 12.45

ATRA (ATRA) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan. 12.97 12.39 13.73 9.75
Feb. 13.92 12.78 14.72 13.16
Mar. 13.15 12.33 13.64 9.60
Apr. 12.00 11.26 13.12 14.15
May. 12.70 11.79 13.54 12.95
Jun. 12.66 11.87 13.49 12.04
Jul. 13.46 13.04 14.33 9.02
Aug. 13.48 12.44 13.93 10.68
Sep. 13.54 12.68 13.96 9.19
Oct. 12.92 12.04 13.68 12.01
Nov. 11.37 10.99 11.77 6.61
Dec. 10.70 10.22 11.67 12.44

Atara Biotherapeutics forecast for this year


Atara Biotherapeutics Stock Prediction for Jan 2025

An uptrend is forecast for this month with an optimal target price of $12.9666. Pessimistic: $12.39. Optimistic: $13.73


Atara Biotherapeutics Stock Prediction for Feb 2025

An uptrend is forecast for this month with an optimal target price of $13.9157. Pessimistic: $12.78. Optimistic: $14.72


Atara Biotherapeutics Stock Prediction for Mar 2025

An downtrend is forecast for this month with an optimal target price of $13.1476. Pessimistic: $12.33. Optimistic: $13.64


Atara Biotherapeutics Stock Prediction for Apr 2025

An downtrend is forecast for this month with an optimal target price of $11.9958. Pessimistic: $11.26. Optimistic: $13.12


Atara Biotherapeutics Stock Prediction for May 2025

An uptrend is forecast for this month with an optimal target price of $12.7012. Pessimistic: $11.79. Optimistic: $13.54


Atara Biotherapeutics Stock Prediction for Jun 2025

An downtrend is forecast for this month with an optimal target price of $12.6555. Pessimistic: $11.87. Optimistic: $13.49


Atara Biotherapeutics Stock Prediction for Jul 2025

An uptrend is forecast for this month with an optimal target price of $13.4603. Pessimistic: $13.04. Optimistic: $14.33


Atara Biotherapeutics Stock Prediction for Aug 2025

An uptrend is forecast for this month with an optimal target price of $13.4765. Pessimistic: $12.44. Optimistic: $13.93


Atara Biotherapeutics Stock Prediction for Sep 2025

An uptrend is forecast for this month with an optimal target price of $13.5412. Pessimistic: $12.68. Optimistic: $13.96


Atara Biotherapeutics Stock Prediction for Oct 2025

An downtrend is forecast for this month with an optimal target price of $12.9237. Pessimistic: $12.04. Optimistic: $13.68


Atara Biotherapeutics Stock Prediction for Nov 2025

An downtrend is forecast for this month with an optimal target price of $11.3729. Pessimistic: $10.99. Optimistic: $11.77


Atara Biotherapeutics Stock Prediction for Dec 2025

An downtrend is forecast for this month with an optimal target price of $10.7041. Pessimistic: $10.22. Optimistic: $11.67



Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 10.22 9.30 10.72 13.27
Feb 11.09 10.30 11.43 9.89
Mar 11.95 11.49 12.37 7.07
Apr 11.46 10.89 12.52 13.07
May 11.08 10.32 11.52 10.39
Jun 10.52 10.13 10.89 6.96
Jul 10.18 9.80 10.90 10.09
Aug 9.25 8.48 9.51 10.74
Sep 8.48 8.17 8.69 5.98
Oct 8.76 8.37 9.00 7.01
Nov 7.93 7.23 8.62 16.22
Dec 8.56 8.19 9.27 11.64

Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 8.13 7.47 8.80 15.07
Feb 8.49 7.88 9.06 13.04
Mar 8.56 8.02 9.06 11.45
Apr 7.71 6.99 8.42 16.92
May 7.33 7.08 8.03 11.82
Jun 7.08 6.70 7.63 12.24
Jul 6.27 5.89 6.52 9.70
Aug 6.35 6.10 6.58 7.30
Sep 6.48 6.26 6.90 9.24
Oct 6.09 5.59 6.26 10.63
Nov 6.09 5.94 6.46 8.14
Dec 6.79 6.29 7.30 13.95

Atara Biotherapeutics information and performance

Atara Biotherapeutics Address

611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, US

Market Capitalization: 70 154 000 $

Market capitalization of the Atara Biotherapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ATRA shares in the company outstanding by the market price of one share.

EBITDA: -162 124 992 $

EBITDA of Atara Biotherapeutics is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -25.32

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 28.93
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 0.526

Enterprise Value (EV) /Revenue

EV To EBITDA: -0.347

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 5759800

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.